• Username (E-mail)
  • Password
Dow 19,827 -0.3%  EStoxx50 3,285 -0.3%  Nikkei 18,814 -1.5%  EUR 1.0708 0.0% 
Nasdaq 5,539 -0.6%  FTSE100 7,220 -1.5%  Yen 112.7080 0.0%  Oil 55.5 -0.4% 
S&P500 2,268 -0.3%  DAX 11,540 -0.1%  GBP 1.2401 0.0%  Gold 1,216 0.0% 

Celgene share [Symbol: CELG / ISIN: US1510201049]

Realtimequote Celgene Corp. in USD

Exchange Market
114.93
Last
454,888
Volume
Time 04:00 PM
01/17/2017 04:00:00 PM UTC-0500
activate push

Stock Price Celgene Corp. in USD

Activate push
114.95 USD -2.53 USD -2.15 %
Trade Time 5:20 PM Trade Date 1/17/2017
Daily High 116.36 Open 116.36
Daily Low 113.22 Prev. Close 114.95
52-week High 127.00 Volume (Qty.) 1,723,834
52-week Low 93.06 Market Cap (USD) 92.14 B
52-week Perf.
Exchange

Analyst Opinions for Celgene Corp.

More Analyst Opinions
  • All
  • Buy
  • Hold
  • Sell
01/08/13
Celgene Stifel, Nicolaus & Co., Inc.
01/08/13
Celgene RBC Capital Markets
01/04/13
Celgene RBC Capital Markets
01/02/13
Celgene RBC Capital Markets
12/14/12
Celgene Goldman Sachs Group Inc.

Moody's Rating for Celgene Corp.

Investment Grade (High Grade)
Investment Grade (Medium Grade)
Speculative Grade
Rating Baa2
Rating Update DNG
Date of Rating 8/3/2015
Rating Office USA

Profile Celgene Corp.

Company Profile
Celgene Corp. is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. Celgene was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.
pagehit

Add or Edit Instrument

Celgene Chart - 1 Year - NAS
  • Intraday
  • 1w
  • 3 Mo.
  • 1y
  • 3y
  • 5y
  • Max
  • Exchange: NAS
  • Chart Options

Estimates for Celgene

2015 2016e 2017e
Dividend - - -
Dividend Yield in % - - -
P/E Ratio 25.47 19.48 16.23
EPS 4.71 5.92 7.10

Celgene Key Figures

Market Cap (USD) 92.14 B
Free Float in % 99.75
Number of Shares (Mio.) 775.20
Cash Flow per Share 4.70
Book Value per Share 9.16
60-Days Volatility 36.97
P/B Ratio 13.10

Base Data Celgene

Symbol CELG
ISIN US1510201049
Indices S&P 500, NASDAQ 100, BX Swiss - USA

About the Company Celgene

Country USA

Celgene Historical Prices

01/12/2017
01/12/2017 06:00:00 PM UTC-0500
117.48 1,126,079
01/11/2017
01/11/2017 06:00:00 PM UTC-0500
117.08 1,162,451
01/10/2017
01/10/2017 06:00:00 PM UTC-0500
117.24 1,997,171
01/09/2017
01/09/2017 06:00:00 PM UTC-0500
119.98 1,388,067
01/08/2017
01/08/2017 06:00:00 PM UTC-0500
120.21 2,026,928

Celgene Peer Group

Abbott Laboratories 40.90
-0.1%
AstraZeneca 45.32
-0.9%
Bayer 100.70
-0.4%
Bristol-Myers Squibb 56.28
0.1%
Celgene 114.95
-2.2%
GlaxoSmithKline 15.53
-1.8%
Johnson & Johnson 114.87
0.2%
Merck 61.48
-1.4%
Novartis 71.45
-1.0%
Pfizer 32.06
-1.4%

Similar shares with higher 1-year perf.